Radiofrequency echographic multi-spectrometry and prolactinoma: case report
A. S. Shutova,
L. K. Dzeranova,
E. A. Pigarova,
S. Yu. Vorotnikova,
U. V. Buyvalenko,
M. A. Perepelova,
A. G. Kuzmin https://doi.org/10.14341/omet13197
Abstract
In case of prolactin-secreting pituitary adenomas, the attention of patients and physicians is drawn to the clinical manifestations of pituitary adenoma, including associated metabolic disorders. The success of conservative methods of treating prolactinomas, the development and implementation of new approaches to the treatment of aggressive and resistant pituitary adenomas allow us to focus on non-obvious pathological conditions accompanying prolactin-secreting adenomas. These include secondary bone metabolism disorders with decreased bone mineral density (BMD), leading to osteoporosis and low-traumatic fractures. The key to effective prevention and treatment of osteoporosis is timely and accurate diagnostics, but not all methods for determining BMD developed to date can be characterized in this way. This paper highlights the use of new methods for diagnosing osteoporosis in the context of its high risk in hormonally active pituitary adenomas, in particular in prolactinomas, using a real clinical case as an example
About the Authors
A. S. Shutova
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Aleksandra S. Shutova
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
L. K. Dzeranova
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Larisa K. Dzeranova, ScD
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
E. A. Pigarova
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Ekaterina A. Pigarova, MD, PhD
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
S. Yu. Vorotnikova
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Svetlana Y. Vorotnikova, MD
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
U. V. Buyvalenko
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Uliana V. Buyvalenko
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
M. A. Perepelova
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Margarita A. Perepelova
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
A. G. Kuzmin
The National Medical Research Center for Endocrinology
Russian Federation
Competing Interests:
Russian Federation
Anatoly G. Kuzmin, MD, PhD
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
None
References
1. Giperprolaktinemiya v praktike ginekologa: etiologiya, patogenez, klinika, diagnostika, lechenie / OR Grigoryan, AA Larina, EN Andreeva, GA Mel'nichenko // Problemy reprodukcii. 2013;4:14-20. Ilovajskaya, IA. Giperprolaktinemiya v akushersko-ginekologicheskoj praktike / I.A. Ilovajskaya // Akusherstvo i ginekologiya. 2017;4:149-154 (In Russ.)
2. Tritos NA, Miller KK. Diagnosis and Management of Pituitary Adenomas: A Review. JAMA. 2023 Apr 25;329(16):1386-1398. doi: 10.1001/jama.2023.5444. PMID: 37097352.
3. Colao A. The prolactinoma. Best Practice & Research Clinical Endocrinology & Metabolism. 2009;5(23):575-596
4. Kalmykova ZA, Vorotnikova SY, Fedorova NS, Dzeranova LK, Pigarova EA, Vorontsov .V. The efficacy of high-dose cabergoline treatment of prolactinomas resistant to standard doses: a clinical observation. Obesity and metabolism. 2019;16(2):89-94. (In Russ.) doi: https://doi.org/10.14341/omet10243
5. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2011;96(2):273–88. doi: https://doi.org/10.1210/jc.2010-1692
6. Coss D, Yang L, Kuo CB, Xu X, Luben RA, Walker AM. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab. 2000;279:E1216–25
7. Seriwatanachai D, Thongchote K, Charoenphandhu N, Pandaranandaka J, Tudpor K, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 2008;42:535–46
8. Krishnamra N, Seemoung J. Effects of acute and long-term administration of prolactin on bone 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol. 1996;74:1157–65
9. Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, Krishnamra N. Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int. 2008;32:1126–35
10. Mazziotti G, Frara S, Giustina A. Pituitary Diseases and Bone. Endocr Rev. 2018 Aug 1;39(4):440-488. doi: https://doi.org/10.1210/er.2018-00005
11. Naliato ECO, Farias MLF, Braucks GR, Costa FSR, Zylberberg D, Violante AHD. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest. 2005;28(3):12-17. doi: https://doi.org/10.1007/BF03345523
12. Zhao Y, Gan X, Luo P, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945-948. doi: https://doi.org/10.3109/09513590.2012.683080
13. Belaya ZhE, Belova KYu, Biryukova EV, Dedov II, Dzeranova LK, et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021;24(2):4-47. doi: https://doi.org/10.14341/osteo12930
14. Dedov II, Mel’nichenko GA, Mokrysheva NG, Pigarova EA, Povaliaeva AA, et al. Draft federal clinical practice guidelines for the diagnosis, treatment, and prevention of vitamin D deficiency. Osteoporosis and Bone Diseases. 2021;24(4):4-26. (In Russ.). doi: https://doi.org/10.14341/osteo12937
15. Pigarova EA, Rozhinskaya L.Ya., Belaya Zh.E., Dzeranova L.K., Karonova T.L., Ilyin A.V., Melnichenko G.A., Dedov I.I. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.) doi: https://doi.org/10.14341/probl201662460-84
16. Melnichenko GA, Belaya ZhE, Rozhinskaya LYa, Grebennikova TA, Pigarova EA, et al. Summary of clinical guidelines for the diagnosis and treatment of osteoporosis of the Russian association of endocrinologists. Osteoporosis and Bone Diseases. 2016;19(3):28-36. (In Russ.) doi: https://doi.org/10.14341/osteo2016328-36
17. Fonseca H, Moreira-Gonçalves D, Coriolano H-JA, Duarte JA. Bone Quality: The Determinants of Bone Strength and Fragility. Sport Med. 2014;44(1):37-53. doi: https://doi.org/10.1007/s40279-013-0100-7
18. Caffarelli C, Tomai Pitinca MD, Al Refaie A, Ceccarelli E, Gonnelli S. Ability of radiofrequency echographic multispectrometry to identify osteoporosis status in elderly women with type 2 diabetes. Aging Clin Exp Res. 2022;34(1):121-127. doi: https://doi.org/10.1007/s40520-021-01889-w
19. Conversano F, Franchini R, Greco A, et al. A Novel Ultrasound Methodology for Estimating Spine Mineral Density. Ultrasound Med Biol. 2015;41(1):281-300. doi: https://doi.org/10.1016/j.ultrasmedbio.2014.08.017
20. Di Paola M, Gatti D, Viapiana O, et al. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int. 2019;30(2):391-402. doi: https://doi.org/10.1007/s00198-018-4686-3
Supplementary files
|
|
1. Figure 1. Comparison of spine dual-energy X-ray absorptiometry and radiofrequency echographic multi-spectrometry of patient Z., initial study. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(737KB)
|
Indexing metadata ▾ | |
|
|
2. Figure 2. Comparison of femur dual-energy X-ray absorptiometry and radiofrequency echographic multi-spectrometry of patient Z., initial study. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(680KB)
|
Indexing metadata ▾ | |
|
|
3. Figure 3. Comparison of spine dual-energy X-ray absorptiometry and radiofrequency echographic multi-spectrometry of patient Z., 12 months follow-up. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(772KB)
|
Indexing metadata ▾ | |
|
|
4. Figure 4. Comparison of femur dual-energy X-ray absorptiometry and radiofrequency echographic multi-spectrometry of patient Z., in 12 months follow-up. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(708KB)
|
Indexing metadata ▾ | |
|
|
5. Figure 5. Densitometeres EchoStation и EchoS Echolight. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(618KB)
|
Indexing metadata ▾ | |
Review
For citations:
Shutova A.S., Dzeranova L.K., Pigarova E.A., Vorotnikova S.Yu., Buyvalenko U.V., Perepelova M.A., Kuzmin A.G. Radiofrequency echographic multi-spectrometry and prolactinoma: case report. Obesity and metabolism. 2024;21(4):431-438. (In Russ.) https://doi.org/10.14341/omet13197
Views:
369
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
